Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

Clinical Lymphoma, Myeloma & Leukemia
Jesus BerdejaRavi Vij

Abstract

The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients with multiple myeloma (MM) and renal impairment. Patients with MM and normal renal function (NRF) (creatinine clearance [CrCl] ≥ 90 mL/min), severe renal impairment (SRI) (CrCl < 30 mL/min, not requiring dialysis), or end-stage renal disease (ESRD) (requiring dialysis) were enrolled in this open-label, phase Ib study. Elotuzumab (10 mg/kg), lenalidomide (5-25 mg), and dexamethasone (40 mg) were administered in 28-day cycles until disease progression or unacceptable toxicity developed. The primary endpoint was single-dose elotuzumab pharmacokinetics. A total of 26 patients (median age, 63 years) were treated (NRF, n = 8; SRI, n = 9; ESRD, n = 9). The median baseline CrCl was 105 mL/min (range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI. Twenty-three patients (89%) had received previous therapy (median, 2 regimens; range, 1-7). Treatment was discontinued in 6 patients with NRF, 4 with SRI, and 5 with ESRD, primarily because of disease progression. The mean elotuzuma...Continue Reading

References

Feb 28, 2007·Leukemia & Lymphoma·V Eleutherakis-PapaiakovouUNKNOWN Greek Myeloma Study Group
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric D HsiMarna B Williams
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel
Jan 18, 2012·Journal of Clinical Pharmacology·Bernd Meibohm, Honghui Zhou
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sagar LonialSundar Jagannath
Aug 28, 2012·Advances in Chronic Kidney Disease·Nelson Leung, Judith Behrens
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosE Kastritis
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators

❮ Previous
Next ❯

Citations

Jan 27, 2016·Drugs·Anthony Markham
May 20, 2016·Expert Opinion on Emerging Drugs·Flora ZagouriMeletios A Dimopoulos
Mar 20, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Leonid GibianskyManish Gupta
Jul 5, 2016·Expert Review of Clinical Immunology·Jean-Samuel BoudreaultPhilippe Moreau
Jul 19, 2016·Expert Review of Hematology·Despoina FotiouEfstathios Kastritis
Aug 26, 2016·Hospital Pharmacy·J Aubrey Waddell, Dominic A Solimando
Aug 18, 2016·Expert Opinion on Biological Therapy·Sagar LonialPaul Richardson
Oct 21, 2016·Expert Opinion on Pharmacotherapy·Maria GavriatopoulouMeletios A Dimopoulos
Nov 3, 2016·Clinical Pharmacology and Therapeutics·J P LaubachD L Longo
Jan 7, 2017·Expert Opinion on Drug Safety·Maria GavriatopoulouMeletios A Dimopoulos
Jan 25, 2017·Expert Review of Hematology·Annamaria BrioliMarie Von Lilienfeld-Toal
Jan 24, 2017·Expert Review of Hematology·Jean-Samuel BoudreaultPhilippe Moreau
Oct 4, 2016·Therapeutic Advances in Hematology·Hermann Einsele, Martin Schreder
Jun 13, 2017·Human Vaccines & Immunotherapeutics·Sabarinath Venniyil RadhakrishnanDjordje Atanackovic
Jun 28, 2017·CPT: Pharmacometrics & Systems Pharmacology·Josiah T Ryman, Bernd Meibohm
Mar 28, 2018·Expert Review of Hematology·Elena ZamagniMichele Cavo
Feb 7, 2018·Cancer·Martin KöhlerMonika Engelhardt
Aug 6, 2016·Therapeutic Advances in Hematology·Hila Magen, Eli Muchtar
Jan 11, 2018·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jill M ComeauGary W Jean
Nov 5, 2019·Expert Review of Anticancer Therapy·Evangelos Eleutherakis-PapaiakovouMeletios A Dimopoulos
Feb 14, 2020·Paediatric Drugs·Zaid H TemrikarBernd Meibohm
Mar 29, 2019·Cephalalgia : an International Journal of Headache·William Kielbasa, Danielle L Helton
Jun 28, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Diane R Mould, Bernd Meibohm
May 22, 2020·Frontiers in Oncology·Arthur BobinXavier Leleu
Jul 16, 2016·Journal of Hematology & Oncology·Yucai WangMichael L Wang
Aug 6, 2017·Clinical Pharmacokinetics·Chaitali PasseyManish Gupta
May 24, 2020·The Journal of Applied Laboratory Medicine·Li LiuSarah E Wheeler
Apr 18, 2018·Oncotarget·Gregory FouquetHicham Bouhlal
Oct 6, 2020·Cytometry. Part B, Clinical Cytometry·Kah Teong SohPaul K Wallace
Nov 8, 2020·Journal of Clinical Medicine·Hélène GardeneyStéphanie Guidez
Jan 23, 2021·Future Oncology·Sebastian GrosickiOlga Grosicka

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay

Software Mentioned

WinNonlin

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.